PGEN – Precigen, Inc.

Float Short %

19.72

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

0.03

EPS Last/This Y

-0.41

EPS This/Next Y

0.7

Price

3.69

Target Price

8.5

Analyst Recom

1.67

Performance Q

2.79

Relative Volume

0.77

Beta

1.11

Ticker: PGEN

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	PGEN	4.9	0.17	0.62	86790
2025-11-18	PGEN	4.84	0.18	0.00	87626
2025-11-19	PGEN	4.22	0.17	0.42	90514
2025-11-20	PGEN	3.9	0.18	0.44	92473
2025-11-21	PGEN	3.89	0.18	0.17	91140
2025-11-24	PGEN	3.82	0.07	0.80	68443
2025-11-25	PGEN	3.66	0.06	0.02	67711
2025-11-26	PGEN	3.75	0.06	0.16	70020
2025-12-01	PGEN	3.61	0.06	0.05	70167
2025-12-02	PGEN	3.48	0.06	0.67	70372
2025-12-03	PGEN	3.58	0.07	0.10	70595
2025-12-04	PGEN	3.77	0.07	0.34	70771
2025-12-05	PGEN	3.61	0.07	0.00	71137
2025-12-08	PGEN	3.7	0.07	0.07	71340
2025-12-09	PGEN	3.52	0.07	0.02	71567
2025-12-10	PGEN	3.51	0.07	0.02	71774
2025-12-11	PGEN	3.62	0.06	0.03	72594
2025-12-12	PGEN	3.71	0.06	0.04	72252
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-17	PGEN	4.90	-	-	-0.39
2025-11-18	PGEN	4.84	-	-	-0.88
2025-11-19	PGEN	4.22	-	-	-0.88
2025-11-20	PGEN	3.89	-	-	-0.88
2025-11-21	PGEN	3.89	-	-	-0.88
2025-11-24	PGEN	3.81	-	-	-0.88
2025-11-25	PGEN	3.67	-	-	-0.88
2025-11-26	PGEN	3.75	-	-	-0.88
2025-12-01	PGEN	3.61	-	-	-0.88
2025-12-02	PGEN	3.48	-	-	-0.88
2025-12-03	PGEN	3.57	-	-	-0.88
2025-12-04	PGEN	3.77	-	-	-0.88
2025-12-05	PGEN	3.60	-	-	-0.88
2025-12-08	PGEN	3.69	-	-	-0.88
2025-12-09	PGEN	3.51	-	-	-0.88
2025-12-10	PGEN	3.51	-	-	-0.88
2025-12-11	PGEN	3.63	-	-	-0.88
2025-12-12	PGEN	3.69	-	-	-0.88
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-17	PGEN	-3.22	5.58	27.97
2025-11-18	PGEN	-3.22	5.58	23.55
2025-11-19	PGEN	-3.22	5.58	23.55
2025-11-20	PGEN	-3.22	5.58	23.55
2025-11-21	PGEN	-3.22	5.58	23.55
2025-11-24	PGEN	-4.54	12.98	23.55
2025-11-25	PGEN	-4.54	12.98	23.55
2025-11-26	PGEN	-4.54	12.98	19.82
2025-12-01	PGEN	-4.54	12.87	19.35
2025-12-02	PGEN	-4.61	12.87	19.35
2025-12-03	PGEN	-4.61	12.87	19.35
2025-12-04	PGEN	-4.61	12.87	19.35
2025-12-05	PGEN	-4.61	12.87	19.35
2025-12-08	PGEN	-4.61	12.98	19.35
2025-12-09	PGEN	-4.61	12.98	19.35
2025-12-10	PGEN	-4.61	12.98	19.72
2025-12-11	PGEN	-4.61	12.98	19.72
2025-12-12	PGEN	-4.61	12.98	19.72
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="PGEN" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.11

Avg. EPS Est. Current Quarter

-0.08

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

-4.61

Institutional Transactions

12.98

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

66.8

Max Drawdown 5-Year %

-93.8

Target Price

8.5

P/E

Forward P/E

PEG

P/S

206.91

P/B

31.18

P/Free Cash Flow

EPS

-1.4

Average EPS Est. Cur. Y

-0.88

EPS Next Y. (Est.)

-0.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6750.13

Relative Volume

0.77

Return on Equity vs Sector %

-1044.1

Return on Equity vs Industry %

-1029.1

EPS 1 7Days Diff

-0.5

EPS 1 30Days Diff

-0.48

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”PGEN” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PGEN” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PGEN” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PGEN” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PGEN” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PGEN” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PGEN” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Precigen, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 143

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

stock quote shares PGEN – Precigen, Inc. Stock Price stock today

news today PGEN – Precigen, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PGEN – Precigen, Inc. yahoo finance google finance

stock history PGEN – Precigen, Inc. invest stock market

stock prices PGEN premarket after hours

ticker PGEN fair value insiders trading

PGEN – Precigen, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PGEN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y